Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2005-10-28 / Mol. Ther. 2006 Jan;13(1):221-8[Current status of hyperthermia for therapy of brain tumor]
/in Glioblastoma, International Publications /von 2005-09-01 / Nippon Rinsho 2005 Sep;63 Suppl 9:483-9Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment
/in Dendritic Cells, Glioblastoma, International Publications /von 2005-08-01 / Clin. Cancer Res. 2005 Aug;11(15):5515-25Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines
/in Glioblastoma, International Publications /von 2005-07-01 / J. Neurosurg. 2005 Jul;103(1):156-64Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial
/in Dendritic Cells, Glioblastoma, International Publications /von 2005-06-01 / Clin. Cancer Res. 2005 Jun;11(11):4160-7Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma
/in Dendritic Cells, Glioblastoma, International Publications /von 2005-04-01 / J. Neurooncol. 2005 Apr;72(2):107-13Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2004-11-01 / Br. J. Cancer 2004 Nov;91(9):1656-62Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12
/in Dendritic Cells, Glioblastoma, International Publications /von 2004-11-01 / J. Immunother. 2004 Nov-Dec;27(6):452-9Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit
/in Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease Virus /von 2004-09-27 / J. Clin. Oncol. 2004 Nov;22(21):4272-81
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de